We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Cogstate is a health information services business based in Australia. Cogstate shares (CGS) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian Dollars. Cogstate has a trailing 12-month revenue of around $32.7 million. If you're looking to buy shares, check out the steps below.
Our top pick for
US stocks
Our top pick for
ETF investing
Our top pick for
Overall broker
| 52-week range | $0.8 - $2.68 |
|---|---|
| 50-day moving average | $2.3564 |
| 200-day moving average | $1.7428 |
| Target price | $1.27 |
| PE ratio | 59.7561 |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $0.041 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the last close of A$2.32
| 1 week (2022-01-13) | -8.30% |
|---|---|
| 1 month (2021-12-21) | 0.87% |
| 3 months (2021-10-21) | 3.57% |
| 6 months (2021-07-21) | 61.67% |
| 1 year (2021-01-21) | 109.95% |
|---|---|
| 2 years (2020-01-20) | 388.42% |
| 3 years (2019-01-17) | 283.79% |
| 5 years (2017-01-20) | 74.73% |
Valuing Cogstate stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Cogstate's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Cogstate's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 60x. In other words, Cogstate shares trade at around 60x recent earnings.
That's relatively high compared to, say, the P/E ratio for the ASX over the 12 months to December 2019 (32.14). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Cogstate's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $4.5 million (£0.0 million).
The EBITDA is a measure of a Cogstate's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $32.7 million |
|---|---|
| Operating margin TTM | 11.73% |
| Gross profit TTM | $17.5 million |
| Return on assets TTM | 5.75% |
| Return on equity TTM | 28.08% |
| Profit margin | 16.01% |
| Book value | 0.127 |
| Market capitalisation | $424.7 million |
TTM: trailing 12 months
We're not expecting Cogstate to pay a dividend over the next 12 months.
Cogstate's shares were split on 5 August 2008.
Over the last 12 months, Cogstate's shares have ranged in value from as little as $0.8 up to $2.68. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while Cogstate's is -0.2537. This would suggest that Cogstate's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Cogstate has bucked the trend.
Cogstate Limited, a cognitive science company, provides computerized cognitive tests for clinical trials, academic research, healthcare, and brain health applications in Australia and internationally. The company's services include project management, data management, scientific consulting, statistical analysis, scales procurement, rater training, and monitoring solutions. It operates in Clinical Trials and Healthcare segments. The Clinical Trials segment provides technology and associated services that are used to quantify the effect of diseases and drugs, and devices or other interventions on human subjects participating in clinical trials primarily conducted by pharmaceutical and biotechnology companies. The Healthcare segment provides Cognigram, a system for regular and standardized testing to assist in the early detection of cognitive decline. As of June 30, 2021, it had participated in approximately 1,800 academic research studies in approximately 200 indications. Cogstate Limited was incorporated in 1999 and is based in Fitzroy, Australia.
It can be confusing knowing the difference between a KN95 and N95 face mask. We look at them both and where to buy them online.
Here’s what Ryan Edwards-Pritchard learned so far about building a startup in the grips of a pandemic.
Arsenal and Liverpool are locked at 0-0 ahead of their Carabao Cup semi-final second leg this week.
Heres how stock levels and prices are holding up for RATs in Australia.
Learn how to stake OHM and receive high yield from one of DeFi's most ambitious experiments.
Being early to a new DeFi ecosystem can be very profitable – here's how to game the system and potentially earn yourself some tokens.
Reporting season is a 2-week or so period where investors can see the results for a large number of publicly traded companies.
Bank First’s variable rate green personal loan can be used to make environmentally friendly purchases for your home.
The 10 biggest movers on the ASX for Thursday 20 January 2022.
